pharmaceutical drugs

Printer-friendly version
Federal government not being honest about true cost of national pharmacare

Support among Canadians for national pharmacare drops from 79 per cent to 40 per cent when the plan is linked to tax hikes.

Printer-friendly version
Ottawa postpones short-sighted drug-pricing regulations

Planned changes would likely result in fewer new and innovative drugs available to Canadians.

Printer-friendly version
Colorado wants your drugs

If every U.S. prescription was filled in Canada, the annual Canadian drug supply would be exhausted in 52 days.

Printer-friendly version
Trudeau government advisors prescribe vast bureaucracy to manage national pharmacare

Unfortunately, the federal government’s track record of creating reliable and accurate data systems is not good.

Printer-friendly version

Of the 53,109 ADR reports received in 2012, almost 80 per cent were categorized as “serious.”

Printer-friendly version

Canadian patients may be denied new innovative drugs and other health technologies emerging for the treatment of chronic diseases such as cancer.

Printer-friendly version

Since 2000, at least five provincial studies, plus a Senate report have concluded that the annual growth in government health spending is not sustainable. At the same time government spending on prescription drugs - both patented and non-patented - is increasing faster than any other part of health spending. And new or patented medicines can be very expensive compared to older drugs and other health treatments. Some therefore blame patented medicines for unsustainable health care costs in Canada.